Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

被引：91

作者：

Papamichael, D

Gallagher, CJ

Oliver, RTD

Johnson, PW

Waxman, J

机构：

[1] UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND

[2] ST JAMES UNIV HOSP,DEPT MED ONCOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND

[3] HAMMERSMITH HOSP,DEPT MED ONCOL,LONDON,ENGLAND

来源：

BRITISH JOURNAL OF CANCER | 1997年 / 75卷 / 04期

关键词：

paclitaxel; bladder cancer; transitional cell carcinoma;

D O I：

10.1038/bjc.1997.106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m(-2) administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients was modest. The response rates were one partial response (PR) (7%) and three stable disease (SD). There were two early deaths.

引用

页码：606 / 607

页数：2

共 11 条

[1]

DEHAVEN J, 1995, P AM ASSOC CANC RES, V36, pA1765

[2]

DREICER R, 1996, P AM SOC CLIN ONCOL, V15, pA607

[3] EUROPEAN-CANADIAN RANDOMIZED TRIAL OF PACLITAXEL IN RELAPSED OVARIAN-CANCER - HIGH-DOSE VERSUS LOW-DOSE AND LONG VERSUS SHORT INFUSION [J].